🌐 IPOPI joined the EU Commission’s HTA Stakeholder Network, connecting with colleagues like Dr Claire Booth.
Working together for faster patient access to innovation at fair prices.
#EUHTA #HTA #HealthPolicy
Working together for faster patient access to innovation at fair prices.
#EUHTA #HTA #HealthPolicy
July 2, 2025 at 9:45 AM
🌐 IPOPI joined the EU Commission’s HTA Stakeholder Network, connecting with colleagues like Dr Claire Booth.
Working together for faster patient access to innovation at fair prices.
#EUHTA #HTA #HealthPolicy
Working together for faster patient access to innovation at fair prices.
#EUHTA #HTA #HealthPolicy
And so it begins! First request period open for companies seeking scientific advice #euhta #healthunion
ec.europa.eu/newsroom/san...
ec.europa.eu/newsroom/san...
Health Technology Assessment: The Commission opens first request submission period for joint scientific consultations
ec.europa.eu
February 3, 2025 at 11:39 PM
And so it begins! First request period open for companies seeking scientific advice #euhta #healthunion
ec.europa.eu/newsroom/san...
ec.europa.eu/newsroom/san...
📢 Report Now Available!
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
December 30, 2025 at 2:49 PM
📢 Report Now Available!
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing
becarispublishing.com
February 5, 2026 at 1:58 PM
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
European Commission adopts final implementing regulation for #JointClinicalAssessments under the #EUHTA framework | Becaris Publishing becarispublishing.com/digital-cont...
European Commission adopts final implementing regulation for joint clinical assessments under the EU HTA framework | Becaris Publishing
becarispublishing.com
October 20, 2025 at 3:24 PM
European Commission adopts final implementing regulation for #JointClinicalAssessments under the #EUHTA framework | Becaris Publishing becarispublishing.com/digital-cont...
Launching in Europe now requires more than regulatory approval. Discover how AI-powered Continuous Intelligence helps improve EU HTA readiness, reimbursement planning, and market access.
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
July 2, 2026 at 6:08 AM
Launching in Europe now requires more than regulatory approval. Discover how AI-powered Continuous Intelligence helps improve EU HTA readiness, reimbursement planning, and market access.
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
First #JCA was completed under the #EUHTA Regulation with Ireland, member of the Beneluxa Initiative, in the assessor role. Congratulations to #NCPE and @iqwig.bsky.social on reaching this milestone! At the Beneluxa Initiative, we now look into how we can incorporate JCAs into our joint processes.
May 12, 2026 at 9:12 AM
First #JCA was completed under the #EUHTA Regulation with Ireland, member of the Beneluxa Initiative, in the assessor role. Congratulations to #NCPE and @iqwig.bsky.social on reaching this milestone! At the Beneluxa Initiative, we now look into how we can incorporate JCAs into our joint processes.
Our latest publication, Opportunities For and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era, has been featured in the Journal of Market Access and Health Policy. Read more: www.mdpi.com/2001-6689/13...
#EUHTA #HTAR #Vaccines
#EUHTA #HTAR #Vaccines
June 18, 2025 at 11:14 AM
Our latest publication, Opportunities For and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era, has been featured in the Journal of Market Access and Health Policy. Read more: www.mdpi.com/2001-6689/13...
#EUHTA #HTAR #Vaccines
#EUHTA #HTAR #Vaccines
📣 A new article is out in the Journal of Market Access & Health Policy as part of the Special Issue on #EUHTA.
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
January 18, 2026 at 8:00 AM
📣 A new article is out in the Journal of Market Access & Health Policy as part of the Special Issue on #EUHTA.
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
🩺 𝗘𝘂𝗿𝗼𝗽ä𝗶𝘀𝗰𝗵𝗲 𝗚𝗲𝘀𝘂𝗻𝗱𝗵𝗲𝗶𝘁𝘀𝗱𝗮𝘁𝗲𝗻 𝘂𝗻𝗱 𝗘𝗨-𝗡𝘂𝘁𝘇𝗲𝗻𝗯𝗲𝘄𝗲𝗿𝘁𝘂𝗻𝗴: 𝗪𝗶𝗲 𝗽𝗿𝗼𝗳𝗶𝘁𝗶𝗲𝗿𝗲𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗶𝗻𝗻𝗲𝗻 𝘂𝗻𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻?
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
December 4, 2025 at 1:06 PM
🩺 𝗘𝘂𝗿𝗼𝗽ä𝗶𝘀𝗰𝗵𝗲 𝗚𝗲𝘀𝘂𝗻𝗱𝗵𝗲𝗶𝘁𝘀𝗱𝗮𝘁𝗲𝗻 𝘂𝗻𝗱 𝗘𝗨-𝗡𝘂𝘁𝘇𝗲𝗻𝗯𝗲𝘄𝗲𝗿𝘁𝘂𝗻𝗴: 𝗪𝗶𝗲 𝗽𝗿𝗼𝗳𝗶𝘁𝗶𝗲𝗿𝗲𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗶𝗻𝗻𝗲𝗻 𝘂𝗻𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻?
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
🚨 Latest Industry Update from JCER highlights new era of #EUHTA
Explore the challenges & opportunities it brings, plus insights on cost–effectiveness methods & NICE’s severity modifier, in latest article from Ramagopalan et al.
🔗Read here: becarispublishing.com/doi/10.57264...
#MarketAccess #HTAR
Explore the challenges & opportunities it brings, plus insights on cost–effectiveness methods & NICE’s severity modifier, in latest article from Ramagopalan et al.
🔗Read here: becarispublishing.com/doi/10.57264...
#MarketAccess #HTAR
Access in all areas? A roundup of developments in market access and health technology assessment: part 6
In this update, we discuss an article covering the implementation challenges of the
upcoming European Union Health Technology Assessment regulation, particularly focusing
on the complexity of populati...
becarispublishing.com
January 13, 2025 at 2:22 PM
🚨 Latest Industry Update from JCER highlights new era of #EUHTA
Explore the challenges & opportunities it brings, plus insights on cost–effectiveness methods & NICE’s severity modifier, in latest article from Ramagopalan et al.
🔗Read here: becarispublishing.com/doi/10.57264...
#MarketAccess #HTAR
Explore the challenges & opportunities it brings, plus insights on cost–effectiveness methods & NICE’s severity modifier, in latest article from Ramagopalan et al.
🔗Read here: becarispublishing.com/doi/10.57264...
#MarketAccess #HTAR
In case you missed it, our latest whitepaper provides a practical guide to closing the rare disease product timeline gap; evidence transportability, external control arms, sample-size preservation in real-world evidence, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug #RWE
#EUHTA #JCA #OrphanDrug #RWE
September 9, 2026 at 10:02 AM
In case you missed it, our latest whitepaper provides a practical guide to closing the rare disease product timeline gap; evidence transportability, external control arms, sample-size preservation in real-world evidence, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug #RWE
#EUHTA #JCA #OrphanDrug #RWE
If you're developing a therapy for a rare disease, we recommend you check out our new whitepaper, a practical guide to closing that gap: evidence transportability, external control arms, sample-size preservation in #RWE, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug
#EUHTA #JCA #OrphanDrug
August 21, 2026 at 10:00 AM
If you're developing a therapy for a rare disease, we recommend you check out our new whitepaper, a practical guide to closing that gap: evidence transportability, external control arms, sample-size preservation in #RWE, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug
#EUHTA #JCA #OrphanDrug
From 2028, orphan drugs face EU JCA built on RCTs, validated endpoints, and standard of care rare diseases rarely have. Read our new whitepaper exploring how to build a defensible evidence package anyway.
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
July 28, 2026 at 11:00 AM
From 2028, orphan drugs face EU JCA built on RCTs, validated endpoints, and standard of care rare diseases rarely have. Read our new whitepaper exploring how to build a defensible evidence package anyway.
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
Joint Clinical Assessment leads Brussels: HTACG Itvisma SMA JCA + AI rules; RSV + open CHMP/NICE.
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
July 20, 2026 at 5:57 AM
Joint Clinical Assessment leads Brussels: HTACG Itvisma SMA JCA + AI rules; RSV + open CHMP/NICE.
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
December 7, 2025 at 8:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
October 26, 2025 at 8:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9